Louise I Robinson

US Patent:

6525091, Feb 25, 2003

Filed:

Feb 22, 2002

Appl. No.:

10/082802

Inventors:

Louise Robinson - San Carlos CA
Hugo O. Villar - La Jolla CA

Assignee:

Telik, Inc. - South San Francisco CA

International Classification:

A61K 3117

US Classification:

514517, 514518, 514522, 514597, 514598, 558 24, 558 37, 558413, 564 49, 564 50, 564 51

Abstract:

Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful in methods of treating autoimmune diseases, infectious diseases, and malignancies.

US Patent:

6600069, Jul 29, 2003

Filed:

Sep 6, 2001

Appl. No.:

09/949165

Inventors:

Louise Robinson - San Carlos CA
Prasad V. V. S. V. Manchem - South San Francisco CA
Nicolas Cairns - Burlingame CA
Steven R. Schow - Redwood Shores CA

Assignee:

Telik, Inc. - Palo Alto CA

International Classification:

C07C30935

US Classification:

562 54, 562452, 562453, 562455, 562573, 564153, 514381, 514553, 514563, 514616, 514674, 548250

Abstract:

Compounds of Formula I, and pharmaceutical compositions containing these compounds, activate the insulin receptor kinase, which leads to an increased sensitivity to insulin and an increase in glucose uptake, and are therefore useful for the treatment of animals, especially humans, with hyperglycemia, especially for the treatment of type 2 diabetes. Processes for preparation of the compounds, and their use in assays, are also disclosed.

US Patent:

6670364, Dec 30, 2003

Filed:

Jan 29, 2002

Appl. No.:

10/060967

Inventors:

Edgardo Laborde - Foster City CA
Louise Robinson - San Carlos CA
Fanying Meng - San Francisco CA
Brian T. Peterson - San Francisco CA
Hugo O. Villar - La Jolla CA
Steven E. Anuskiewicz - San Bruno CA
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Assignee:

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co., Ltd. - Nagoya

International Classification:

A61P 2900

US Classification:

51425304, 514303, 5142342, 51425211, 514218, 540575, 544127, 544121, 544362, 544357, 546120

Abstract:

The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

US Patent:

6677365, Jan 13, 2004

Filed:

Mar 25, 2002

Appl. No.:

10/106881

Inventors:

Edgardo Laborde - Foster City CA
Louise Robinson - San Carlos CA
Fanying Meng - San Francisco CA
Brian T. Peterson - San Francisco CA
Hugo O. Villar - La Jolla CA
Steven E. Anuskiewicz - San Bruno CA
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Assignee:

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co., Ltd.

International Classification:

A61K 3142

US Classification:

514379, 514301, 514302, 514303, 514367, 514394, 514405, 546114, 546115, 546118, 546120, 548180, 548217, 5483044, 5483611

Abstract:

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

US Patent:

6809113, Oct 26, 2004

Filed:

Feb 27, 2002

Appl. No.:

10/087208

Inventors:

Edgardo Laborde - Foster City CA
Louise Robinson - San Carlos CA
Fanying Meng - San Francisco CA
Brian T. Peterson - San Francisco CA
Hugo O. Villar - La Jolla CA
Steven E. Anuskiewicz - San Bruno CA
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Assignee:

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co. - Nagoya

International Classification:

A61K 3135

US Classification:

514456, 514256, 514337, 514356, 514363, 549 60, 549366, 548136, 548146, 548204, 548253, 548254, 5462827, 544333, 544335

Abstract:

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

US Patent:

6962926, Nov 8, 2005

Filed:

Aug 8, 2003

Appl. No.:

10/637746

Inventors:

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - Mountain View CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Wenli Ma - Mountain View CA, US
Yukiharu Matsumoto - Gifu, JP
Kunihisa Baba - Yokkaichi, JP
Hideaki Inagaki - Inabe, JP
Katsumasa Tanaka - Inabe, JP
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Masayuki Okamoto - Tokyo-to, JP
Takashi Nakamura - Kuwana, JP
Atsushi Miyachi - Kuwana, JP
Mitsuaki Takeuchi - Inabe, JP
Kouji Matsushima - Matsudo, JP

Assignee:

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co., Ltd. - Nagoya

International Classification:

A61K031/437
A61K031/496
C61K031/5377
C07D471/04
A61P029/00

US Classification:

514303, 51421707, 5142342, 51425304, 546120, 546119, 544127, 544362, 540597, 540599

Abstract:

Compounds of formula A and formula B: and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The compounds are antagonists of MCP-1 function, and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis, and in the prevention and treatment of allergic hypersensitivity disorders.

US Patent:

6992086, Jan 31, 2006

Filed:

Nov 17, 2003

Appl. No.:

10/716363

Inventors:

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - San Francisco CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Assignee:

Telik, Inc. - Palo Alto CA

International Classification:

A61K 31/496
A61K 31/437
C07D 498/04
C07D 471/04
A61P 37/00

US Classification:

51425304, 514302, 5142342, 514303, 51425211, 514218, 540575, 544127, 544362, 544121, 544357, 546115, 546120

Abstract:

The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

US Patent:

6998407, Feb 14, 2006

Filed:

Nov 18, 2003

Appl. No.:

10/716652

Inventors:

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - San Francisco CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Assignee:

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co. Ltd. - Nagoya

International Classification:

A61K 31/36
A61K 31/343
C07D 307/79
C07D 317/60

US Classification:

514301, 514302, 514440, 514443, 514465, 514466, 514469, 546114, 546115, 549 15, 549 57, 549436, 549462, 549466, 549468, 549470

Abstract:

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.